Company intelligence / Profile preview

Introspect Health

Berlin, Berlin, Germanypmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

Introspect develops integrated digital therapeutics designed to be combined with pharmacological treatments for mental health disorders. The platform aims to improve safety and effectiveness of therapies such as ketamine for treatment-resistant depression by providing personalized care management and developing digital biomarkers. Clinical results are not independently reported but are part of broader studies conducted by atai Life Sciences.

Therapeutic areas: Psychiatry
Modalities: Digital therapeuticCombination therapy (digital + pharmacological)
Industry: Digital Health Medical Devices

Partnerships

All partnerships are through parent company atai Life Sciences; no independent major pharma partnerships listed.

Beyond the preview

Go deeper on Introspect Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Introspect Health.

Explore the full profile